country

Change Language

EN - English
FR - Français
DE - Deutsch
ES - Español
JA - 日本語
KO - 한국어

Country or Region:

United States

Product Name	Size / Unit Price	Qty

Total: USD 0.00 Checkout

Cat. No.: HY-182679

Copy Link Print Information

L0909

L0909 is an HCV inhibitor with an EC₅₀ of 0.022 μM. L0909 blocks HCV replication by inhibiting E1-mediated viral entry. L0909 exhibits sensitivity to clinical resistant HCV mutants. L0909 displays synergistic effects with clinical HCV drugs. L0909 can be used for the research of hepatitis c virus (HCV) infection.

연구목적의 판매만을 진행합니다. 환자를 대상으로 한 판매는 하지 않습니다.

CAS No.: 2085271-43-6
화학식: C₂₃H₃₀ClN₅
분자량:411.97

보관:

Please store the product under the recommended conditions in the Certificate of Analysis.

L0909 Chemical Structure

CAS No.: 2085271-43-6

Amount: USD 0.00

* 장바구니에 담기 전 물품의 수량을 선택해 주십시오.

Use of MCE Products

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biological Activity
- 제품 설명
- Cellular Effect
- In Vitro
- Parmacokinetics
- In Vivo
Chemical Information
순도&문서
References
Calculators
Help & FAQs
Classifications
Bioz

Biological Activity

제품 설명

Cellular Effect

Cell Line	Type	Value	Description	References
Huh-7.5	CC₅₀	121.47 μM Compound: L0909	Cytotoxicity against human Huh7.5 cells carrying HCV subgenomic replicons assessed as reduction in cell viability incubated for 96 hrs by MTT assay Cytotoxicity against human Huh7.5 cells carrying HCV subgenomic replicons assessed as reduction in cell viability incubated for 96 hrs by MTT assay	[PMID: 35050619]

In Vitro

L0909 (72 h) potently inhibits HCV RNA replication in Huh7.5 cells (CC₅₀ = 14.77 μM) with an EC₅₀ of 0.022 μM^[1].
L0909 (-chloro) (72 h) potently inhibits HCV replication in Huh7.5 cells (CC₅₀ = 12.761 μM) with an EC₅₀ of 0.083 μM and a selectivity index of 154^[1].
L0909 (0.1-5 μM; 3-14 days) does not inhibit HCV replication in replicon GS4.3 cells^[1].
L0909 (0.3125-12.5 μM; 4-72 h) blocks HCV entry into Huh7.5 cells, exhibiting potent, rapid, and broad-spectrum activity against both genotype 1b and 2a HCV pseudoparticles and replicating virus^[1].
L0909 inhibits HCV entry via targeting the HCV E1 glycoprotein, as evidenced by the F291V E1 mutation conferring ~20-fold resistance to the compound in Huh7.5 cells^[1].
L0909 (serial dilutions; 72 h) retains potent, nanomolar activity against drug-resistant HCV variants (A156T, D168V, S282T) in Huh7.5 cells, similar to its activity against wild-type HCV^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Real Time qPCR^[1]

Cell Line:

Wild-type and drug-resistant HCV mutants (A156T NS3, D168V NS3, S282T NS5B)-infected Huh7.5 cells
Concentration:

Serial dilutions
Incubation Time:

72 h
Result:

Maintained potent activity against all tested drug-resistant mutants: EC₅₀ = 0.0019 μM (A156T NS3), 0.03 μM (D168V NS3), 0.0044 μM (S282T NS5B), compared to an EC₅₀ of 0.003 μM against wild-type HCV.

Parmacokinetics

Species	Dose	Route	T_1/2	T_max	C_max	V_z	CL	F
Rat^[1]	5 mg/kg	i.v.	14.34 h	/	616.99 ng/mL	20057.05 mL/kg	1088.11 mL/h/kg	/
Rat^[1]	15 mg/kg	p.o.	12.83 h	3.08 h	500.72 ng/mL	34834.07 mL/kg	2246.3 mL/h/kg	59 %
Dog^[1]	5 mg/kg	i.v.	7.28 h	/	531.93 ng/mL	49181.42 mL/kg	4752.98 mL/h/kg	/
Dog^[1]	15 mg/kg	p.o.	12.72 h	3 h	94.51 ng/mL	238116.97 mL/kg	12025.86 mL/h/kg	39 %

In Vivo

L0909 (250-1000 mg/kg; i.g.,; single dose) has an oral maximal tolerated dose above 1000 mg/kg in Kunming mice, with no observed mortality, body weight changes, or liver/kidney function abnormalities over 7 days^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

Kunming mice (male and female, 3 each per group)^[1]
Dosage:

250 mg/kg; 500 mg/kg; 1000 mg/kg
Administration:

p.o.; single dose
Result:

Showed no mortality across all treatment groups over 7 days.
Detected no significant changes in body weight compared to the control group.
Found no significant abnormalities in blood AST, ALT, UREA, or CRE levels at any tested dose, including 1000 mg/kg.

Related Protocols :

Research Protocol for Infectious Diseases

Chemical Information

CAS No. 2085271-43-6
분자량 411.97
화학식 C₂₃H₃₀ClN₅
SMILES

N#CC1=CC=C(N(CCN(C)C)C)C=C1CN2CCN(CC2)C3=CC=C(C=C3)Cl
선적

Room temperature in continental US; may vary elsewhere.
보관

Please store the product under the recommended conditions in the Certificate of Analysis.

순도&문서

Handling Instructions (2659 KB)

References

[1]. Jiang X, et al. 2-((4-Arylpiperazin-1-yl)methyl)benzonitrile Derivatives as Orally Available Inhibitors of Hepatitis C Virus with a Novel Mechanism of Action. J Med Chem. 2020 Jun 11;63(11):5972-5989. [Content Brief]

Calculators

몰농도 계산기

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

농도 희석 계산기

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Bioz

Keywords

MOQ

Minimum order quantity

100 mg

견적 받기 해외재고보유

Other size

견적 받기